Interactions of processed Nef (58-206) with virion proteins of HIV type 1

AIDS Research and Human Retroviruses

Volumn 20, Issue 4, 2004, Pages 399-407

  Ciuffi, Angela ^a   Munoz, Miguel ^a   Bleiber, Gabriela ^b   Favre, Manuel ^a   Stutz, Francoise ^a   Telenti, Amalio ^a,b   Meylan, Pascal R A ^a,b  

^a UNIVERSITY OF LAUSANNE   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; INTEGRASE; ISOPROTEIN; NEF PROTEIN; VIRUS ENZYME;

ANALYTIC METHOD; ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOPRECIPITATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN PROCESSING; PROTEIN PROTEIN INTERACTION; TWO HYBRID SYSTEM; VIRION; YEAST;

GENE PRODUCTS, NEF; HIV INTEGRASE; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; PROTEIN BINDING; TWO-HYBRID SYSTEM TECHNIQUES; VIRAL CORE PROTEINS; VIRION;

EID: 2342561010     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922204323048140     Document Type: Article

References (70)

1. Deacon NJ, Tsykin A, Solomon A, Smith K, Ludford-Menting M, Hooker DJ, McPhee DA, Greenway AL, Ellett A, and Chatfield C: Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995;270: 988-991.
2. Kestler HW, III, Ringler DJ, Mori K, Panicali DL, Sehgal PK, Daniel MD, and Desrosiers RC: Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991;65:651-662.
3. Hanna Z, Kay DG, Rebai N, Guimond A, Jothy S, and Jolicoeur P: Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998; 95:163-175.
4. Peter F: HIV nef: the mother of all evil? Immunity 1998;9:433-437.
5. Cullen BR: HIV-1 auxiliary proteins: Making connections in a dying cell. Cell 1998;93:685-692.
6. Marsh JW: The numerous effector functions of Nef. Arch Biochem Biophys 1999;365:192-198.
7. Piguiet V and Trono D: The Nef protein of primate lentiviruses. Rev Med Virol 1999;9:111-120.
8. Ameisen JC: Apoptosis subversion: HIV-Nef provides both armor and sword. Nat Med 2001;7:1181-1182.
9. Ameisen JC: Apoptosis subversion: HIV-Nef provides both armor and sword. Nat Med 2001;7:1181-1182.
10. Arold ST and Baur AS: Dynamic Nef and Nef dynamics: How structure could explain the complex activities of this small HIV protein. Trends Biochem Sci 2001;26:356-363.
11. Geyer M, Fackler OT, and Peterlin BM: Structure-function relationships in HIV-1 Nef. EMBO Rep 2001;2:580-585.
12. Geyer M and Peterlin BM: Domain assembly, surface accessibility and sequence conservation in full length HIV-1 Nef. FEBS Lett 2001;496:91-95.
13. Greene WC and Peterlin BM: Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med 2002;8:673-680.
14. Garcia JV and Miller AD: Serine phosphorylation-independent downregulation of cell-surface CD4 by nef. Nature 1991;350: 508-511.
15. Mariani R and Skowronski J: CD4 down-regulation by nef alleles isolated from human immunodeficiency virus type 1-infected individuals. Proc Natl Acad Sci USA 1993;90:5549-5553.
16. Anderson SJ, Lenburg M, Landau NR, and Garcia JV: The cytoplasmic domain of CD4 is sufficient for its down-regulation from the cell surface by human Immunodeficiency virus type 1 Nef. J Virol 1994;68:3092-3101.
17. Schwartz O, Marechal V, Le Gall S, Lemonnier F, and Heard JM: Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. Nat Med 1996;2:338-342.
18. Le Gall S, Erdtmann L, Benichou S, Berlioz-Torrent C, Liu L, Benarous R, Heard JM, and Schwartz O: Nef interacts with the mu subunit of clathrin adaptor complexes and reveals a cryptic sorting signal in MHC I molecules. Immunity 1998;8:483-495.
19. Collins KL, Chen BK, Kalams SA, Walker BD, and Baltimore D: HIV-1 Nef protein protects infected primary cells against killing by cytotoxic T lymphocytes. Nature 1998;391:397-401.
20. Collins KL and Baltimore D: HIV's evasion of the cellular immune response. Immunol Rev 1999;168:65-74.
21. Piguet V, Schwartz O, Le Gall S, and Trono D: The downregulation of CD4 and MHC-I by primate lentiviruses: A paradigm for the modulation of cell surface receptors. Immunol Rev 1999;168: 51-63.
22. Renkema GH and Saksela K: Interactions of HIV-1 NEF with cellular signal transducing proteins. Front Biosci 2000;5:D268-D283.
23. Fackler OT and Baur AS: Live and let die. Nef functions beyond HIV replication. Immunity 2002;16:493-497.
24. Swingler S, Mann A, Jacque J, Brichacek B, Sasseville VG, Williams K, Lackner AA, Janoff EN, Wang R, Fisher D, and Stevenson M: HIV-1 Nef mediaets lymphocyte chemotaxis and activation by infected macrophages. Nat Med 1999;5:97-1103.
25. Chowers MY, Spina CA, Kwoh TJ, Fitch NJ, Richman DD, and Guatelli JC: Optimal infectivity in vitro of human immunodeficiency virus type 1 requires an intact nef gene. J Virol 1994; 68:2906-2914.
26. Jamieson BD, Aldrovandi GM, Planelles V, Jowett JB, Gao L, Bloch LM, Chen IS, and Zack JA: Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J Virol 1994;68:3478-3485.
27. Miller MD, Warmerdam MT, Gaston I, Greene WC, and Feinberg MB: The human immunodeficiency virus-1 nef gene product: A positive factor for viral infection and replication in primary lymphocytes and macrophages. J Exp Med 1994;179:101-113.
28. Spina CA, Kwoh TJ, Chowers MY, Guatelli JC, and Richman DD: The importance of nef in the induction of human immunodeficiency virus type 1 replication from primary quiescent CD4 lymphocytes. J Exp Med 1994;179:115-123.
29. Glushakova S, Grivel JC, Suryanarayana K, Meylan P, Lifson JD, Desrosiers R, and Margolis L: Nef enhances human immunodeficiency virus replication and responsiveness to interleukin-2 in human lymphoid tissue ex vivo. J Virol 1999;73:3968-3974.
30. Chowers MY, Pandori MW, Spinal CA, Richman DD, and Guatelli JC: The growth advantage conferred by HIV-1 nef is determined at the level of viral DNA formation and is independent of CD4 downregulation. Virology 1995;212:451-457.
31. Goldsmith MA, Warmerdam MT, Atchison RE, Miller MD, and Greene WC: Dissociation of the CD4 downregulation and viral infectivity enhancement functions of human immunodeficiency virus type 1 Nef. J Virol 1995;69:4112-4121.
32. Saksela K, Cheng G, and Baltimore D: Proline-rich (PxxP) motifs in HIV-1 Nef bind to SH3 domains of a subset of Src kinases and are required for the enhanced growth of Nef+ viruses but not for down-regulation of CD4. EMBO J 1995;14:484-491.
33. Lama J, Mangasarian A, and Trono D: Cell-surface expression of CD4 reduces HIV-1 infectivity by blocking Env incorporation in a Nef- and Vpu-inhibitable manner. Curr Biol 1999;9:622-631.
34. Aiken C and Trono D: Nef stimulates human immunodeficiency virus type 1 proviral DNA synthesis. J Virol 1995;69:5048-5056.
35. Miller MD, Warmerdam MT, Page KA, Feinberg MB, and Greene WC: Expression of the human immunodeficiency virus type 1 (HIV-1) nef gene during HIV-1 production increases progeny particle infectivity independently of gp160 or viral entry. J Virol 1995;69:579-584.
36. Pandori MW, Fitch NJ, Craig HM, Richman DD, Spina CA, and Guatelli JC: Producer-cell modification of human immunodeficiency virus type 1: Nef is a virion protein. J Virol 1996;70: 4283-4290.
37. Kotov A, Zhou J, Flicker P, and Aiken C: Association of Nef with the human immunodeficiency virus type 1 core. J Virol 1999;73: 8824-8830.
38. Freund J, Kellner R, Konvalinka J, Wolber V, Krausslich HG, and Kalbitzer HR: A possible regulation of negative factor (Nef) activity of human immunodeficiency virus type 1 by the viral protease. Eur J Biochem 1994;223:589-593.
39. Welker R, Kottler H, Kalbitzer HR, and Krausslich HG: Human immunodeficiency virus type 1 Nef protein is incorporated into virus particles and specifically cleaved by the viral proteinase. Virology 1996;219:228-236.
40. Bukovsky AA, Dorfman T, Weimann A, and Gottlinger HG: Nef associatino with human immunodeficiency virus type 1 virions and cleavage by the viral protease. J Virol 1997;71:1013-1018.
41. Miller MD, Warmerdam MT, Ferrell SS, Benitez R, and Greene WC: Intravirion generation of the C-terminal core domain of HIV-1 Nef by the HIV-1 protease is insufficient to enhance viral infectivity. Virology 1997;234:215-225.
42. Chen YL, Trono D, and Camaur D: The proteolytic cleavage of human immunodeficiency virus type 1 Nef does not correlate with its ability to stimulate virion infectivity. J Virol 1998;72: 3178-3184.
43. Pandori M, Craig H, Moutouh L, Corbeil J, and Guatelli J: Virological importance of the protease-cleavage site in human immunodeficiency virus type 1 Nef is independent of both intravirion processing and CD4 down-regulation. Virology 1998;251:302-316.
44. Gervaix A, West D, Leoni LM, Richman DD, Wong-Staal F, and Corbeil J: A new reporter cell line to monitor HIV infection and drug susceptibility in vitro. Proc Natl Acad Sci USA 1997; 94:4653-4658.
45. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A, and Martin MA: Production of acquired immunodeficiency syndrome-associated retrovirus ini human and nonhuman cells transfected with an infectious molecular clone. J Virol 1986;59: 284-291.
46. Bleiber G, Munoz M, Ciuffi A, Meylan P, and Telenti A: Individual contributions of mutant protease and reverse transcriptase to viral infectivity, replication, and protein maturation of antiretroviral drug-resistant human immunodeficiency virus type 1. J Virol 2001;75:3291-3300.
47. Harlow E and Lane D: Immunoaffinity purification. In: Antibodies, A Laboratory Manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1998, pp. 511-552.
48. Stutz F, Kantor J, Zhang D, McCarthy T, Neville M, and Rosbash M: The yeast nucleoporin rip 1p contributes to multiple export pathways with no essential role for its FG-repeat region. Genes Dev 1997;11:2857-2868.
49. Stutz F, Neville M, and Rosbash M: Identification of a novel nuclear pore-associated protein as a functional target of the HIV-1 Rev protein in yeast. Cell 1995;82:495-506.
50. Strahm Y, Fahrenkrog B, Zenklusen D, Rychner E, Kantor J, Rosbach M, and Stutz F: The RNA export factor Gle1p is located on the cytoplasmic fibrils of the NPC and physically interacts with the FG-nucleoporin Rip1p, the DEAD-box protein Rat8p/Dbp5p and a new protein Ymr 255p. EMBO J 1999;18:5761-5777.
51. Craig HM, Pandori MW, and Guatelli JC: Interaction of HIV-1 Nef with the cellular dileucine-based sorting pathway is required for CD4 down-regulation and optimal viral infectivity. Proc Natl Acad Sci USA 1998;95:11229-11234.
52. Craig HM, Reddy TR, Riggs NL, Dao PP, and Guatelli JC: Interactions of HIV-1 nef with the mu subunits of adaptor protein complexes 1, 2, and 3: Role of the dileucine-based sorting motif. Virology 2000;271:9-17.
53. Ren R, Mayer BJ, Cicchetti P, and Baltimore D: Identification of a ten-amino acid proline-rich SH3 binding site. Science 1993; 259:1157-1161.
54. Piguet V, Wan L, Borel C, Mangasarian A, Demaurex N, Thomas G, and Trono D: HIV-1 Nef protein binds to the cellular protein PACS-I to downregulate class I major histocompatibility complexes. Nat Cell Biol 2000;2:163-167.
55. Kalpana GV and Goff SP: Genetic analysis of homomeric interactions of human immunodeficiency virus type 1 integrase using the yeast two-hybrid system. Proc Natl Acad Sci USA 1993;90: 10593-10597.
56. Jenkins TM, Engelman A, Ghirlando R, and Craigie R: A soluble active mutant of HIV-1 integrase: Involvement of both the core and carboxyl-terminal domains in multimerization. J Biol Chem 1996;271:7712-7718.
57. Zheng R, Jenkins TM, and Craigie R: Zinc folds the N-terminal domain of HIV-1 integrase, promotes multimerization, and enhances catalytic activity. Proc Natl Acad Sci USA 1996;93: 13659-13664.
58. Muller B, Restle T, Weiss S, Gautel M, Sczakiel G, and Goody RS: Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. J Biol Chem 1989;264: 13975-13978.
59. Lee CH, Saksela K, Mirza UA, Chait BT, and Kuriyan J: Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell 1996;85:931-942.
60. Turner BG and Summers MF: Structure biology of HIV. J Mol Biol 1999;285:1-32.
61. Forshey BM and Aiken C: Disassembly of human immunodeficiency virus type 1 cores in vitro reveals association of nef with the subviral ribonucleoprotein complex. J Virol 2003;77: 4409-4414.
62. Wiskerchen M and Cheng-Mayer C: HIV-1 Nef association with cellular serine kinase correlates with enhanced virion infectivity and efficient proviral DNA synthesis. Virology 1996;224:292-301.
63. Jacque JM, Mann A, Enslen H, Sharova N, Brichacek B, Davis RJ, and Stevenson M: Modulation of HIV-1 infectivity by MAPK, a virion-associated kinase. EMBO J 1998;17:2607-2618.
64. Oldridge J and Marsh M: Nef - an adaptor adaptor? Trends Cell Biol 1998;8:302-305.
65. Ovod V, Lagerstedt A, Ranki A, Gornbert FO, Spohn R, Tahtinen M, Jung G, and Krohn KJ: Immunological variation and immunohistochemical localization of HIV-1 Nef demonstrated with monoclonal antibodies. AIDS 1992;6:25-34.
66. Murti KG, Brown PS, Ratner L, and Garcia JV: Highly localized tracks of human immunodeficiency virus type 1 Nef in the nucleus of cells of a human CD4+ T-cell line. Proc Natl Acad Sci USA 1993;90:11895-11899.
67. Ranki A, Lagerstedt A, Ovod V, Aavik E, and Krohn KJ: Expression kinetics and subcellular localization of HIV-1 regulatory proteins Nef, Tat and Rev in acutely and chronically infected lymphoid cell lines. Arch Virol 1994;139:365-378.
68. Schaeffer E, Geleziunas R, and Greene WC: Human immunodeficiency virus type 1 Nef functions at the level of virus entry by enhancing cytoplasmic delivery of virions. J Virol 2001;75: 2993-3000.
69. Zhou J and Aiken C: Nef enhances human immunodeficiency virus type 1 infectivity resulting from intervirion fusion: evidence supporting a role for Nef at the virion envelope. J Virol 2001; 75:5851-5859.
70. Khan M, Garcia-Barrio M, and Powell MD: Restoration of wildtype infectivity to human immunodeficiency virus type 1 strains lacking nef by intravirion reverse transcription. J Virol 2001;75: 12081-12087.